Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Mais filtros

Filtros aplicados
Base de dados
Intervalo de ano de publicação
Int J Gynaecol Obstet ; 62(Suppl. 1): S31-6, Aug. 1998.
Artigo em Inglês | MedCarib | ID: med-1402


Cyclo-Provera, the original name of the combination of 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate, later known as Cyclofem and hereafter referred to MPA/E2C, has proven its use- effectiveness (pregnancy rate less than 1 percent) in routine service delivery conditions. Overall, the life-table discontinuation rates at 1 year ranged from 33.5 percent to 71.8 percent. Only a third of total discontinuations were attributable to the injectable contraceptive method, thus raising the importance of service delivery issues related to its continued use. The results of introductory trials in Mexico, Indonesia, Thailand, Tunisia, Jamaica and, more recently, Brazil, Colombia, Chile and Peru have demonstrated that MPA/E2C is a highly effective contraceptive that could be offered as an alternative to current fertility regulation methods for many women around the world. In addition, the results of studies were the basis for the approval of MPA/E2C by local health authorities and its inclusion in the Ministries of Health Family Planning Programs.(Au)

Feminino , Humanos , Anticoncepcionais Femininos , Países em Desenvolvimento , Estradiol/análogos & derivados , Conhecimentos, Atitudes e Prática em Saúde , Acetato de Medroxiprogesterona , Anticoncepcionais Orais Combinados/efeitos adversos , Anticoncepcionais Orais Combinados/química , Preparações de Ação Retardada , Serviços de Planejamento Familiar/métodos , Injeções Intramusculares , Tábuas de Vida , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Gravidez/estatística & dados numéricos , Estudos Prospectivos , Fatores Socioeconômicos , Anticoncepcionais Femininos/efeitos adversos , Anticoncepcionais Femininos/química , Estradiol/efeitos adversos , Estradiol/química
J Clin Epidemiol ; 48(19): 1513-47, 1995.
Artigo em Inglês | MedCarib | ID: med-2023


A hospital-based, case-control study of the association between current usage of oral contraceptives and first-time cases of acute myocardial infarction, stroke, or a venous thromboembolic event (deep vein thrombiosis or pulmonary embolus) was carried out in 17 countries from four regions (Africa, Europe, Asia, and Latin America, [including Jamaica]). A total of 3792 cases and 10,281 hospitalised controls matched for age were recruited during a 4-year period, ending June 1993. The study was designed to have sufficient power to detect a relative risk of 2 for developing each of the three study diseases, associated with current oral contraceptive use in each of the four regions, with the exception of acute myocardial infarction (for which all non European regions were combined) and for venous thromboembolic events in Asia, where these disorders are rare. This report describes the background, pilot study, methods, and the analyses carried out to validate the methods used in the study. (Au)

Adulto , Resumo em Inglês , Feminino , Humanos , Anticoncepcionais Orais Combinados/efeitos adversos , Transtornos Cerebrovasculares/induzido quimicamente , Estudos de Casos e Controles , Inquéritos e Questionários , Métodos , Jamaica
Contraception ; 49(5): 489-507, May 1994.
Artigo em Inglês | MedCarib | ID: med-7155


Studies on the introduction of Cyclofem into family planning programmes have been undertaken in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Cyclofem is a once-a-month injectable contraceptive containing 25mg medroxyprogesterone acetate and 5mg estradiol cypionate. A total of 7927 subjects were followed in close to routine service delivery conditions in primary and secondary family planning outlets. The studies confirmed the high efficacy of the method with 12-month pregnancy rates ranging from 0 to 0.7 percent. Major differences were seen in reasons and rates of discontinuation between countries, the overall 12-month life table discontinuation rates ranging from 33.5 percent in Indonesia to 71.8 percent in Tunisia. The reasons for discontinuation in each of the five countries described, differences between countries contrasted, and service delivery issues which should be addressed further, raised (AU)

Humanos , Feminino , Gravidez , Adolescente , Adulto , Anticoncepcionais Femininos/administração & dosagem , Estradiol/análise , Serviços de Planejamento Familiar , Acetato de Medroxiprogesterona/administração & dosagem , Anticoncepcionais Orais Combinados/administração & dosagem , Anticoncepcionais Orais Combinados/efeitos adversos , Estradiol/administração & dosagem , Estradiol/efeitos adversos , Indonésia , Acetato de Medroxiprogesterona/efeitos adversos , México , Satisfação do Paciente , Projetos Piloto , Gravidez , Tailândia , Tunísia , Organização Mundial da Saúde
Contraception ; 20(1): 29-48, July 1979.
Artigo em Inglês | MedCarib | ID: med-8032


To study the question of whether one brand of oral contraceptives may be as acceptable as another for use in publicly-assisted family planning programs, a double blind study of two well-known brands, Ovral and Norinyl, was undertaken in Costa Rica and Trinidad. The pills were randomly assigned to 1,200 women. Common side effects - nausea, dizziness, vomiting, headaches - were associated with both Norinyl and Ovral. Differences in event rates for these conditions were much more marked by country than by pill used. Ovral was associated with increases in skin problems, notably chloasma, in Costa Rica. A higher percentage of women using Norinyl reported intermentstral bleeding and spotting in both countries. In Costa Rica continuation rated for Norinyl were adversely affected by this. With these exceptions there appear to be no important differences between the brands that would affect their use in family planning programs (AU)

Humanos , Adolescente , Adulto , Feminino , Anticoncepcionais Orais , Anticoncepcionais Orais Combinados , Costa Rica , Método Duplo-Cego , /farmacologia , Mestranol/farmacologia , Noretindrona , Norgestrel/farmacologia , Trinidad e Tobago , Hemorragia Uterina/etiologia